Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiran Du

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
International Journal of Medical Microbiology : IJMM|October 20, 2024
Genomic Analysis and Virulence Assessment of Hypervirulent Klebsiella pneumoniae K16-ST660 in Severe Cervical Necrotizing FasciitisJun Huang, Jiaru Zhuang, Lin Wan, et al.
Translational Neuroscience|February 23, 2026
A Two-way Mendelian randomisation study of inflammatory factors and the risk of meningiomaJiming Sun, Xinlei Yang, Han Gao, et al.
Frontiers in Immunology|May 7, 2025
Low-dose cyclophosphamide combined with chinese herbal medicine Shuli Fenxiao formula for the treatment of intermediate-to-high risk primary membranous nephropathyYiran Du, Yuning Liu, Zhiyan Chen, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
International Journal of Medical Microbiology : IJMM|October 20, 2024
Genomic Analysis and Virulence Assessment of Hypervirulent Klebsiella pneumoniae K16-ST660 in Severe Cervical Necrotizing FasciitisJun Huang, Jiaru Zhuang, Lin Wan, et al.
Translational Neuroscience|February 23, 2026
A Two-way Mendelian randomisation study of inflammatory factors and the risk of meningiomaJiming Sun, Xinlei Yang, Han Gao, et al.
Frontiers in Immunology|May 7, 2025
Low-dose cyclophosphamide combined with chinese herbal medicine Shuli Fenxiao formula for the treatment of intermediate-to-high risk primary membranous nephropathyYiran Du, Yuning Liu, Zhiyan Chen, et al.
Pageof 2